Stockscreener 앱 받기
150.63
3.61%
-5.64
Novartis Ag Adr 주식(NVS)의 최신 뉴스
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
Novartis AG Lobbying Profile, 2004 - OpenSecrets
Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo
Novartis (NVS) Gains European Commission Approval for Cosentyx i - GuruFocus
European Commission OKs Novartis' Cosentyx for Treatment of Polymyalgia Rheumatica - marketscreener.com
Novartis receives European Commission approval for Cosentyx(R) in polymyalgia rheumatica (PMR) - marketscreener.com
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) - GlobeNewswire
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) - Yahoo Finance
Novartis AG Bills, 2012 - OpenSecrets
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026 - Novartis
Novartis AG : UBS gives a Neutral rating - marketscreener.com
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Novartis AG (NVS) Options ChainYahoo Finance - Yahoo! Finance Canada
Enterprise value to revenue forward of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView
Novartis: The Sell-Off Creates An Attractive Entry Point (NYSE:NVS) - Seeking Alpha
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much? - Yahoo Finance
Novartis Discontinues Mid-Stage Fabhalta Trial in Lupus Nephritis for Strategic Reasons - Yahoo Finance
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition - Reuters
Novartis AG (NVSD.BA) valuation measures and financial statistics - Yahoo Finance Australia
Novartis AG (NOVN.VI) interactive stock chart - Yahoo Finance UK
Novartis AG (NVS) Stock forecasts - Yahoo Finance UK
RBC Capital Remains a Hold on Novartis AG (NOVN) - The Globe and Mail
Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada
Novartis wins Rhapsido approval as Bank of America keeps CHF 150 target for Novartis stock - ad-hoc-news.de
Novartis AG : RBC is Neutral - www.marketscreener.com
IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - StreetInsider
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis AG (NVS) Stock Forecasts - Yahoo Finance
Novartis AG (NOT.F) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Genentech Wins Judge's OK Of $18M Novartis Award - Law360
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100 - GuruFocus
US biotech company enforces eye treatment award against Novartis - Global Arbitration Review
Why Novartis (NVS) Stock Is Up Today - Quiver Quantitative
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Law firm probes Novartis over possible securities fraud after trial failure drops shares 14%. - Pluang
Community health takes a village: Screening in the barber’s chair - Novartis
Novartis AG NVSEF Stock Forecast & Price Target - Yahoo! Finance Canada
NOVARTIS AG N (NOT.HA) Q2 FY2026 earnings call transcript - Yahoo Finance
Novartis AG Rises Monday - Moomoo
Swiss Blue-chip Index Starts Week Upbeat; Roche, Novartis Shares Gain - marketscreener.com
Weekly Recap: Abogen mRNA T‑cell engager investment and Rhapsido approval - TradingView
Novartis AG (CEUX:1NOVNm) Stock PDF (Updated: 2026/10/10) - GuruFocus
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Novartis AG (NOVN.VI) income statement - Yahoo Finance UK
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark - Novartis
0.73%
자본화:
|
볼륨(24시간):